ArticlePsychopharmacology2025
Chronic administration of methocinnamox, a mu-opioid receptor antagonist, reduces hedonic response without impacting motivation in mice.
Article in Psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationaleGenetic and pharmacological studies suggest that signaling through the mu opioid receptor (MOR) is essential for motivation to seek, and hedonic response to, both drugs of abuse as well as natural rewards. Given that impairments in hedonic reactivity and motivation are key behavioral features of depression, we wondered whether sustained deficits in endogenous opioid signaling in adulthood could produce these 'depression-related' behavioral phenotypes.
objectivesTo investigate the effect of chronic MOR blockade in adulthood on motivation and hedonic response to a food reward, as well as whether these behavioral variables are correlated at the individual animal level.
methodsWe chronically administered the pseudo-irreversible MOR antagonist methocinnamox (MCAM) for three weeks prior to assessing motivation and hedonic reactivity for a food reward in the progressive ratio and lickometer tasks, respectively. We then assessed whether motivation and hedonic response to reward were correlated at the individual animal level.
resultsChronic administration of MCAM decreased hedonic response, while leaving goal-directed motivation intact. In addition, there was a weak negative correlation between motivation and hedonic response in individual mice treated with chronic MCAM, but not control mice.
conclusionsChronic blockade of the MOR decreases hedonic response, without impacting motivation to work for the same reward. Although the different components of reward processing such as motivation and hedonic response may be related, they appear to be dissociable.
Indexed as
Identifiers
40346429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.